News

Medicenna Therapeutics Announces Exciting Webinar on MDNA11 Results

Medicenna Therapeutics Announces Exciting Webinar on MDNA11 Results

Medicenna Therapeutics to Host Webcast on MDNA11 Clinical Findings

Medicenna Therapeutics Corp. (TSX: MDNA, OTCQX: MDNAF), an innovative clinical-stage immunotherapy company, is gearing up to conduct a live webinar where they will delve into the updated clinical data surrounding MDNA11. This engaging session is set for December 10, 2025, at 08:30 AM Eastern Time.

Exploring MDNA11 at the Webcast

During the webinar, Medicenna will share fresh insights from the ABILITY-1 Phase 1/2 Study. This study assesses MDNA11 both as a monotherapy and in conjunction with pembrolizumab, a leading cancer treatment. With the ESMO Immuno-Oncology Congress 2025 as a backdrop for this data sharing, attendees can expect a comprehensive overview presented by Medicenna's management team, alongside key opinion leaders who will provide additional commentary on the findings.

Webinar Details for Participants

The live format webinar is designed to be interactive, allowing participants to engage through a Q&A session after the presentation. Here are the key details:

Event Information:

Date: December 10, 2025
Time: 08:30 – 09:30 AM ET
Format: Live Webinar with Q&A
Registration: Interested individuals can secure their spot by registering for the webinar on Medicenna’s official website. A replay will also be made available for those who are unable to attend live.

Key Figures in the Spotlight

The webinar will highlight presentations from a distinguished panel comprising Medicenna's executive team and scientific advisors, including:

Featured Speakers:

1. Dr. Fahar Merchant, President and CEO, known for his vision in the advancement of therapeutics.
2. Dr. Arash Yavari, Director of Clinical Strategy, whose expertise leads the company’s clinical trials.
3. Dr. André Mansinho, Assistant Professor from the Faculty of Medicine, University of Lisbon, will present pivotal findings from the ongoing studies.

About Medicenna: Pioneers in Immunotherapy

Medicenna stands at the cutting edge of immunotherapy, emphasizing the development of novel, selective Superkines, targeting IL-2, IL-4, and IL-13 to combat various cancers and inflammatory conditions. MDNA11, their long-acting IL-2 Superkine, is designed with high affinity to CD122, allowing it to preferentially activate effector T cells and NK cells, crucial in the battle against tumors.

In pursuit of cutting-edge treatment options, Medicenna is also advancing MDNA113, a first-of-its-kind PD-1 x IL-2 bispecific agent, which is engineered using proprietary technologies. Their innovative solutions extend to bizaxofusp (formerly known as MDNA55), which is focused on treating recurrent glioblastoma multiforme—a particularly aggressive form of brain cancer. With successful clinical trials and designations such as FastTrack and Orphan Drug status from health authorities, Medicenna continues its mission to revolutionize cancer treatment.

Contact Information for Queries

For any media or investor-related inquiries, individuals are encouraged to reach out to Shushu Feng from the Investor Relations team at Medicenna. Direct contact can be made at (416) 964-5442 or via email at ir@medicenna.com.

Frequently Asked Questions

What is the purpose of Medicenna's upcoming webinar?

The webinar aims to present updated clinical data on MDNA11 and discuss its implications in cancer treatment.

How can I register for the webinar?

Participants can register through Medicenna's official website for an opportunity to engage in Q&A.

Who are the key speakers for the event?

Key speakers include Dr. Fahar Merchant, Dr. Arash Yavari, and Dr. André Mansinho, who will be sharing valuable insights.

What topics will be covered in the webinar?

The webinar will cover updates on the ABILITY-1 Phase 1/2 Study, focusing on MDNA11’s effectiveness.

How does MDNA11 work?

MDNA11 is designed to selectively stimulate cancer-fighting cells, enhancing their ability to combat tumors while minimizing side effects.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 165

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
Arbor Realty Trust Hit with Securities Fraud Lawsuit

Updated Category News Views 98

Snafu at Arbor Realty: Investors Rethink Strategies You know what puts a bee in my bonnet these days? Misleading statements from companies like Arbor Realty Trust, Inc. (NYSE: ABR). The news breaks that Arbor's got itself neck-deep in a class action lawsuit, courtesy of the sharp folks over at Schall, Brown & Schwartz LLP. Now, this ain't your average financial hiccup....

Continue Reading
Radnostix Sees Mixed Results, Plans Strategic Shift

Updated Category News Views 90

Radnostix: A Rocky Third Quarter with Glimmers of Hope Alright, sit back and digest this: Radnostix, the company once known as International Isotopes Inc., is currently in the midst of a renovation of sorts. They just reported their financial results for the third quarter of 2026, and honestly, they're a mixed bag. Revenue Falls but Theranostics Shines Quarterly revenue...

Continue Reading
Ainstein Expands Kansas Operations Amid Sensor Demand Surge

Updated Category News Views 133

Ainstein's Expansion Conquers New Heights in Radar Tech Ainstein just cranked open a whole new chapter right in the heart of Kansas. And believe me, it's not your average ribbon-cutting story. This shiny new facility in Lenexa is locked and loaded to roll out 44,000 radar sensors a year. It's part of a no-nonsense plan to keep up with soaring demand for their tech across...

Continue Reading
League's AI Launch: A New Era in Healthcare

Updated Category News Views 76

AI: Healthcare's Bold New Move Ah, here we go. Another tech jump in healthcare. This time it's the folks over at League, stirring the pot with some new AI gimmicks. They've slapped together what they call an 'AI Front Door' and an 'AI Care Companion'—part of their Forge by League platform. Now, if there's one thing we know, it's that the healthcare sector loves a good...

Continue Reading
Sharon Stuart's Quest for Her Hidden Origins

Updated Category News Views 123

Delving Into Identity: A Personal Odyssey In a world where everyone seems to be searching for something, Sharon Stuart's quest is etched with the raw need to uncover her real origins. Abandoned as a newborn in the gritty streets of Oakland, she grew up grappling with looming questions about what made her who she is. Her journey is captured in her memoir, "Existing Without...

Continue Reading
Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 126

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading
Chicken Production Rises Amid Meat Market Shifts

Updated Category News Views 165

Protein Markets Scramble: Chicken Production Climbs Here’s a tasty tidbit that might just have investors reeling: the USDA says chicken production will be cruising on the up, whereas beef is taking a bit of a backseat. Yep, the big birds are flying higher, and the cows, well, they're just mooing a little softer. And what's that mean for big players like Tyson...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 69

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
SKE Capitalizes on Halloween Events in London

Updated Category News Views 120

SKE's Bold Step into London's Halloween Vibe Hah! Who would've thought that vaping and Halloween could be a match made in heaven? This year, SKE threw its hat into the ring and wrestled for attention in London’s bustling Halloween music scene. Imagine an entire warehouse pulsing not just with beat-heavy electronic music, but the energy of vaping enthusiasts courtesy of...

Continue Reading

Top 5 Most Recently Viewed Articles

Trua: Veteran-Led Service Offers Senior Living Help

Updated Category News Views 31

A New Chapter for Senior Living Guidance Life's complexities can be as tough as a two-dollar steak, and let's face it, senior living decisions often top that chart. Greater Boston gets a new lifeline with Trua of Greater Boston breaking into the scene. Not just any placement service, mind you. Run by Jersouk Touy and Jessie Marasco, it promises a blend of personalized,...

Continue Reading
Standex International Corporation Reports Q4 Fiscal 2025 Results

Updated Category News Views 162

Standex International Corporation to Announce Q4 2025 Results Standex International Corporation (NYSE: SXI) is set to unveil its financial results for the fourth quarter of fiscal year 2025 on Thursday. The report will be released after the market closes, providing investors and stakeholders with key insights into the company's performance. Key Details of the Announcement...

Continue Reading
Ireland's €3 Billion Bond Sale Highlights Strong Investor Demand

Updated Category News Views 136

Overview of Ireland's Successful Bond Issuance Dublin has recently seen an impressive move in the financial markets with the National Treasury Management Agency successfully issuing €3 billion in 30-year fixed-rate notes. This significant bond issuance demonstrates the strong appetite from investors without the need for stabilization measures, reflecting confidence in...

Continue Reading
Exciting Developments in Yukon Metals' Birch Copper-Gold Project

Updated Category News Views 196

Significant Updates from the Birch Copper-Gold Project Yukon Metals Corp. (CSE: YMC, FSE: E770, OTCQB: YMMCF) has recently announced thrilling developments concerning its 100%-owned Birch Copper-Gold Project, spanning 7,000 hectares. This project is located approximately 65 kilometres from Burwash Landing and 200 kilometres from Whitehorse. The current drill program aims...

Continue Reading
Krystal Biotech's Upcoming Presentation at Major Healthcare Event

Updated Category News Views 122

Krystal Biotech Set to Attend Major Healthcare Conference Krystal Biotech, Inc. (NASDAQ: KRYS), a company dedicated to leading the way in genetic medicine, has shared an exciting opportunity for both investors and the public. The Company will highlight its latest advancements at the upcoming 2024 Cantor Global Healthcare Conference in New York. This event stands out as...

Continue Reading